188 related articles for article (PubMed ID: 34321867)
1. Analysis of Clinical Trials of New Drugs for Liver Diseases in China.
Lin L; Li H
Drug Des Devel Ther; 2021; 15():3181-3191. PubMed ID: 34321867
[TBL] [Abstract][Full Text] [Related]
2. Analysis of clinical trials of new drugs in China as of 2019.
Lin L; Chen Y; Yan L; Liu Y; Ni J; Yang H; Li H
Drug Discov Today; 2020 Dec; 25(12):2080-2088. PubMed ID: 33017690
[TBL] [Abstract][Full Text] [Related]
3. Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA.
Ndugga N; Lightbourne TG; Javaherian K; Cabezas J; Verma N; Barritt AS; Bataller R
BMJ Open; 2017 Mar; 7(3):e013620. PubMed ID: 28336739
[TBL] [Abstract][Full Text] [Related]
4. [Syndrome distribution among patients with chronic hepatitis C and interventions of integrated traditional Chinese and Western medicine: study protocol].
Nie HM; Gao YQ; Chen JJ
Zhong Xi Yi Jie He Xue Bao; 2011 Apr; 9(4):365-73. PubMed ID: 21486548
[TBL] [Abstract][Full Text] [Related]
5. A report from The Liver Meeting 2014 (November 7-11 - Boston, Massachusetts, USA).
Rabasseda X
Drugs Today (Barc); 2014 Nov; 50(11):763-74. PubMed ID: 25525637
[TBL] [Abstract][Full Text] [Related]
6. [Current status and challenges of clinical research and development of new drugs for liver diseases].
Shen ZY; Cai XB; Lu LG
Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):289-294. PubMed ID: 38733180
[TBL] [Abstract][Full Text] [Related]
7. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases.
Rambaldi A; Jacobs BP; Iaquinto G; Gluud C
Cochrane Database Syst Rev; 2005 Apr; (2):CD003620. PubMed ID: 15846671
[TBL] [Abstract][Full Text] [Related]
8. American Association for the Study of Liver Diseases (AASLD)--56th Annual Meeting.
Phend C
IDrugs; 2006 Feb; 9(2):96-100. PubMed ID: 16523396
[No Abstract] [Full Text] [Related]
9. HEP DART 2005 -- frontiers in drug development for viral hepatitis.
Feitelson MA
IDrugs; 2006 Mar; 9(3):165-7. PubMed ID: 16523376
[No Abstract] [Full Text] [Related]
10. Advance in studies on traditional Chinese medicines to treat infection with the hepatitis B virus and hepatitis C virus.
Xia J; Inagaki Y; Song P; Sawakami T; Kokudo N; Hasegawa K; Sakamoto Y; Tang W
Biosci Trends; 2016 Nov; 10(5):327-336. PubMed ID: 27350107
[TBL] [Abstract][Full Text] [Related]
11. [Progress on clinical trials of cancer drugs in China, 2019].
Huang HY; Wu DW; Wang HX; Wang J; Fan Q; Wang SH; Bai Y; Yu Y; Fang Y; Sun C; Fang H; Bai H; Wang X; Liu ZY; Jiang M; Liu Z; Wang XH; Li HY; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):127-132. PubMed ID: 32135647
[No Abstract] [Full Text] [Related]
12. [Systematic evaluation of clinical trial protocols of new drugs as a cure of chronic hepatitis B].
Chen S; Zhao LH; Shan S; Li M; Sun YM; Zhou JL; Wu XN; Dong RH; Kong YY; Ou XJ; Ma H; You H; Jia JD
Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):662-666. PubMed ID: 32911904
[No Abstract] [Full Text] [Related]
13. NIH consensus development statement on management of hepatitis B.
Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
[TBL] [Abstract][Full Text] [Related]
14. Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy.
Ziogas DC; Kostantinou F; Cholongitas E; Anastasopoulou A; Diamantopoulos P; Haanen J; Gogas H
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067316
[TBL] [Abstract][Full Text] [Related]
15. Exploring the effect of Gupi Xiaoji Prescription on hepatitis B virus-related liver cancer through network pharmacology and in vitro experiments.
Yu S; Gao W; Zeng P; Chen C; Zhang Z; Liu Z; Liu J
Biomed Pharmacother; 2021 Jul; 139():111612. PubMed ID: 33915505
[TBL] [Abstract][Full Text] [Related]
16. Natural products as promising drug candidates for the treatment of hepatitis B and C.
Wohlfarth C; Efferth T
Acta Pharmacol Sin; 2009 Jan; 30(1):25-30. PubMed ID: 19060918
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B and hepatitis C in 2009.
Marcellin P
Liver Int; 2009 Jan; 29 Suppl 1():1-8. PubMed ID: 19207959
[TBL] [Abstract][Full Text] [Related]
18. Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma.
Hu Y; Wang S; Wu X; Zhang J; Chen R; Chen M; Wang Y
J Ethnopharmacol; 2013 Oct; 149(3):601-12. PubMed ID: 23916858
[TBL] [Abstract][Full Text] [Related]
19. [The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008].
Pár A; Pár G
Orv Hetil; 2008 Jul; 149(28):1329-32. PubMed ID: 18617461
[No Abstract] [Full Text] [Related]
20. Current status in the therapy of liver diseases.
Uhl P; Fricker G; Haberkorn U; Mier W
Int J Mol Sci; 2014 Apr; 15(5):7500-12. PubMed ID: 24786290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
